USS Investment Management Ltd Reduces Position in Danaher Corporation $DHR

Key Points

• USS Investment Management Ltd reduced its stake in Danaher Corporation by 15.5%, selling 19,571 shares and owning 106,578 shares valued at approximately $21.84 million.
• In the first quarter, several large investors, including Vanguard Group and Invesco Ltd., increased their holdings in Danaher, demonstrating mixed investor sentiment within the institutional space.
• Danaher reported earnings per share of $1.80 for its last quarter, exceeding estimates, and set FY 2025 guidance between 7.700-7.800 EPS.

USS Investment Management Ltd lessened its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 15.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 106,578 shares of the conglomerate's stock after selling 19,571 shares during the quarter. USS Investment Management Ltd's holdings in Danaher were worth $21,841,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DHR. Bank Pictet & Cie Europe AG increased its position in Danaher by 22.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after purchasing an additional 35,730 shares during the period. Full Sail Capital LLC increased its position in Danaher by 2.5% during the 4th quarter. Full Sail Capital LLC now owns 2,730 shares of the conglomerate's stock valued at $627,000 after purchasing an additional 66 shares during the period. Focus Partners Wealth boosted its holdings in shares of Danaher by 19.8% during the 4th quarter. Focus Partners Wealth now owns 177,596 shares of the conglomerate's stock worth $40,818,000 after buying an additional 29,409 shares in the last quarter. Gotham Asset Management LLC boosted its holdings in shares of Danaher by 29.0% during the 4th quarter. Gotham Asset Management LLC now owns 57,043 shares of the conglomerate's stock worth $13,094,000 after buying an additional 12,828 shares in the last quarter. Finally, Humankind Investments LLC boosted its holdings in shares of Danaher by 21.5% during the 4th quarter. Humankind Investments LLC now owns 3,952 shares of the conglomerate's stock worth $907,000 after buying an additional 700 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft cut their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research note on Friday, July 11th. Robert W. Baird boosted their price target on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Barclays restated an "overweight" rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Danaher currently has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.20% of the stock is currently owned by company insiders.

Danaher Stock Performance

Shares of NYSE:DHR traded down $4.39 during midday trading on Tuesday, reaching $194.24. The company had a trading volume of 3,344,891 shares, compared to its average volume of 2,899,976. The company's 50 day moving average price is $201.82 and its 200 day moving average price is $199.20. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock has a market cap of $139.09 billion, a P/E ratio of 41.33, a P/E/G ratio of 2.77 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.